Related Experiment Videos
[Biomedical researches: for whom? for what? how?]
Annales Medico-Psychologiques
|June 1, 1990
Abstract:
The law of December 20th 1988 provides for the protection of those people who lend themselves to clinical research, both patients and healthy subjects. The ex-expert clinicians are confronted with new drugs and protocols of experimentation enacted by industry. Grey areas still exist, authors try to limit them for want of being able to through light on them, today.
Insights
Clinical research laws protect human subjects, including patients and healthy volunteers. However, challenges remain regarding new drugs and experimental protocols, requiring ongoing clarification.
Area of Science:
- Medical Law
- Clinical Trials Ethics
- Pharmaceutical Regulation
Context:
- The legal framework for clinical research protection was established by the December 20th, 1988 law.
- Clinicians face challenges with novel pharmaceuticals and industry-driven experimental protocols.
- Existing ambiguities in clinical research regulations persist.
Purpose:
- To analyze the protective measures for clinical research participants under the 1988 law.
- To examine the implications of new drugs and experimental protocols for clinicians.
- To identify and address the "grey areas" within current clinical research legislation.
Summary:
- The 1988 law offers protection to individuals participating in clinical research, encompassing both patients and healthy volunteers.
- Expert clinicians are encountering new drugs and experimental designs originating from the pharmaceutical industry.
- The authors aim to clarify existing ambiguities in clinical research law and practice.
Impact:
- Enhanced understanding of participant protection in clinical trials.
- Improved guidance for clinicians navigating new drug development and experimentation.
- Potential for regulatory refinement to address identified "grey areas" in clinical research ethics and law.